SYK Stock Price Today (September 2026) — Stryker Corporation Analysis & Key Metrics 2026-09-03
Stryker Corporation (SYK) is trading at $307.99, down 1.35% today (as of September 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $382.72 (24.3% upside).
- Volatility remains elevated (24.99% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (9.40% YoY) alongside significant competitive pressures.
SYK Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Stryker Corporation - Historical Price & Volume
Market Cap
Enterprise Value: $138.81B
P/E Ratio
Forward P/E: 19.33
Revenue Growth
Year over Year
Analyst Target
+24.3% upside potential
Key Investor Questions About SYK
What investors need to know before buying
Based on current market data, SYK presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 31.08)
- Fundamentals say: Caution warranted (high leverage concerns)
SYK's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for SYK investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $15.45B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, SYK stock traded between $281.00 and $396.86—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 24.99% annualized volatility and β=0.56, the stock exhibits low sensitivity to market moves—making SYK suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Stryker Launches FDA-Cleared Apple Vision Pro Surgical App
SYK's FDA-cleared SportSuite Vision brings Apple Vision Pro into hip arthroscopy, strengthening its digital surgery push and Sports Medicine portfolio.
Medical Devices & Supplies - Diversified Stocks Q2 Teardown: Stryker (NYSE:SYK) Vs The Rest
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Stryker (NYSE:SYK) and the best and worst performers in the medical devices & supplies - diversified industry.
ISRG Stock: The Best House On The Block Costs The Most
In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational excellence is worth the premium.
The Wide Divide Priced Into Boston Scientific Stock
The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.
Enovis inks eCential takeover to develop surgical ortho robots
The orthopedics specialist aims to launch a knee robot in late 2028, followed by a shoulder robot in 2029.
Sector Update: Healthcare Stocks Rise Tuesday Afternoon
Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index adding 0.7% and the
Stryker (SYK) Wins FDA Nod And Completes First Procedure With New Surgery Software
Stryker (NYSE:SYK) received FDA De Novo authorization for its SportSuite Vision software on Apple Vision Pro in a clinical setting. The company reported completion of the first surgical procedure using SportSuite Vision in an operating room environment. The software introduces augmented reality and spatial computing tools into surgical workflows and operating room visualization. The authorization marks a regulatory milestone for Stryker in mixed reality applications for healthcare. This...
Stryker to add rotator cuff repair tech with ZuriMED buy
Rotator cuff augmentation is one of the fastest-growing areas in sports medicine, according to Stryker.
Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio
SYK's planned ZuriMED acquisition adds the FiberLocker System, aiming to strengthen its shoulder portfolio and rotator cuff care capabilities.
Is Stryker Stock Underperforming the Nasdaq?
Stryker has considerably underperformed the broader market over the past year, while analysts remain bullish on its future prospects.
Explore More Analysis for SYK
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Stryker Corporation
Stryker Corporation (SYK) is currently trading at $307.99. The RSI (14-day) is at 31.1, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $382.72 implies 24.3% upside from current levels. Volatility is moderate at 25.0% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Stryker Corporation (SYK): The trailing P/E ratio is 31.88, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 19.33, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.52, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 4.92. Price-to-Sales is 4.57. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 25 analysts covering SYK, the consensus price target is $382.72. This represents a 24.3% upside from the current price of $307.99. The range spans from a low target of $315.00 to a high target of $465.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Stryker Corporation (SYK) pays a dividend with a current yield of approximately 1.14%. The annualized dividend rate is $3.48 per share. The payout ratio is 36.1%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-09-30T00:00:00.000Z.
Key risks for Stryker Corporation (SYK) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Stryker Corporation's (SYK) current debt and financial health profile: Total debt stands at $15.45B. The debt-to-equity ratio is 64.39, which is moderate and generally manageable for most companies. The current ratio is 2.16, indicating strong short-term liquidity. The quick ratio is 1.08. The company holds $3.48B in cash and equivalents. Free cash flow is positive at $4.11B, providing a cushion for debt servicing and shareholder returns.